The Evolving Landscape of Advanced Prostate Cancer Treatment: A Guidelines and Case-Based Discussion

The Evolving Landscape of Advanced Prostate Cancer Treatment is a complimentary, comprehensive, guidelines-driven and case-based program designed to equip clinicians with up-to-date strategies for managing complex disease states across the prostate cancer continuum. Faculty will explore multidisciplinary care models, genetic testing, next-generation imaging and theranostics. Case-based discussions will provide practical guidance on treatment selection and sequencing for hormone-sensitive and castration-resistant prostate cancer—including M0 and M1 disease—as well as precision medicine and emerging therapeutic options. Participants will leave with actionable insights to optimize individualized care in an increasingly sophisticated therapeutic landscape.

At the conclusion of this activity, participants will be able to:
PRACTICE GAP #1 (DISEASE STATE)
1. Recognize the natural progression of advanced prostate cancer (APC) from biochemical recurrence (BCR) after local therapy to metastatic hormone-sensitive (M1HSPC) and castration-resistant disease (M0CRPC and M1CRPC).
2. Describe risk and volume stratification, treatment approaches, therapeutic goals, and outcomes for newly diagnosed M1HSPC, including intensification strategies with double or triple therapy (novel hormonal agents and/or chemotherapy).
3. Discuss the role of germline and somatic genetic testing in managing men with high-risk, metastatic prostate cancer and castration-resistant prostate cancer (CRPC) and its implications for treatment.

PRACTICE GAP #2 (GUIDELINES)
4. Provide treatment recommendations for APC based on the AUA/SUO Advanced Prostate Cancer Guidelines.
5. Counsel patients on management strategies for M1HSPC including treatment intensification and deintensification, and sequencing of agents for M1CRPC based on clinical presentation and prior treatment.

PRACTICE GAP #3 (ANDROGEN AXIS)
6. Evaluate the clinical efficacy and optimal use of approved androgen-axis therapeutics both as monotherapy and in combination for the management of APC.
7. Anticipate and manage adverse events arising from androgen-axis targeted agents used in the treatment of APC to optimize outcomes and patient quality of life.

PRACTICE GAP #4 (CHEMOTHERAPY, IMMUNOTHERAPY, PARP INHIBITORS AND THERANOSTICS and COMORBIDITIES)
8. Describe the AUA/SUO guideline-based indications and sequencing for chemotherapy, immunotherapy, PARP Inhibitors and theranostic agents in the management of patients with APC.
9. Identify germline and somatic mutations relevant to M1CRPC and discuss their therapeutic implications including indications for PARP Inhibitor use.

PRACTICE GAP #5 (BONE HEALTH, MANAGING PAIN AND RADIONUCLIDE THERAPY)
10. Integrate advances in bone health management into patient-specific care plans among men with APC.
11. Assess and manage pain in patients with symptomatic M1HSPC and M1CRPC and discuss the role of palliative care and supportive services in the management of late stage M1CRPC.
12. Recommend and prescribe radionuclide therapy in appropriate patients with M1CRPC.

PRACTICE GAP #6 (DEVELOPING AN ADVANCED PROSTATE CANCER CLINIC)
13. Develop a framework for establishing and operationalizing a multidisciplinary prostate cancer clinic.

Acknowledgements:
Support provided by independent educational grants from Astellas, AstraZeneca, Blue Earth Diagnostics, Inc., Lantheus Medical Imaging, Merck & Co. Inc., Novartis Pharmaceuticals Corporation and Pfizer, Inc.

Accreditation:
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation:
The American Urological Association designates this live activity for a maximum of 7.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Learners:
The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.